Perspective of gene therapy for heart failure

Автор: Malishevskiy M.V., Kukarskiy A.Y., Semukhin D.M.

Журнал: Академический журнал Западной Сибири @ajws

Рубрика: Медицина. Внутренние болезни

Статья в выпуске: 3 (64) т.12, 2016 года.

Бесплатный доступ

Короткий адрес: https://sciup.org/140220007

IDR: 140220007

Список литературы Perspective of gene therapy for heart failure

Engelhardt S., Hein L., Dyachenkow. V. et al. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation//Circulation. -2004. -Vol. 109, № 9. -P. 1154-1160.
Milano C.A., Allen L.F., Rockman H.A. et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor//Science. -1994. -Vol. 264, № 5158. -P. 582-586.
Hata J.A., Williams M.L., Koch W.J. Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization//J. Mol. Cell. Cardiol. -2004. -Vol. 37, № 1. -P. 11-21.
Shah A.S., White D.C., Emani S. et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction//Circulation. -2001. -Vol. 103, № 9. -P. 1311-1316.
Katz M.G., Fargnoli A.S., Swain J.D. et al. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve//J. Thorac. Cardiovasc. Surg. -2011. -May. -Vol. 50, № 5. -Р. 766-776.
Gao M.H., Lai N.C., Roth D.M. et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice//Circulation. -1999. -Vol. 99, № 12. -P. 1618-1622.
Lai N.C., Roth D.M., Gao M.H. et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity//Circulation. -2000. -Vol. 102, № 19. -P. 2396-2401.
Kawase Y., Ly H.Q., Prunier F. et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure//J. Am. Coll. Cardiol. -2008. -Vol. 51, № 11. -P. 1112-1119.
Sakata S., Lebeche D., Sakata N. et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins//J. Mol. Cell. Cardiol. -2007. -Vol. 42, № 4. -P. 852-861.
Sakata S., Lebeche D., Sakata Y. et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardio myocyte size in a type 2 diabetic rat model//Am. J. Physiol. Heart. Circ. Physiol. -2007. -Vol. 292, № 2. -P. 1204-1207.
Lyon A.R., Bannister M.L., Collins T. et al. SERCA2a Gene transfer decreases SR calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure//Circ. Arrhythm. Electrophysiol. -2011. -Jun. -Vol. 4, № 3. -P. 362-372.
Cutler M.J., Wan X., Laurita K.R. et al. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans//Circ. Arrhythm. Electrophysiol. -2009. -Vol. 2, № 6. -P. 686-694.
del Monte F., Lebeche D., Guerrero J.L. et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling//Proc. Natl. Acad. Sci. USA. -2004. -Vol. 101, № 15. -P. 5622-5627.
Prunier F., Kawase Y., Gianni D. et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump over-expression in a porcine model of ischemia reperfusion//Circulation. -2008. -Vol. 118, № 6. -P. 614-624.
Hadri L., Bobe R., Kawase Y. et al. SERCA2a Gene Transfer Enhances eNOS Expression and Activity in Endothelial Cells//Molecular Therapy. -2010. -Jul. -Vol. 18, № 7. -P. 1284-1292.
del Monte F., Harding S.E., Dec G.W. et al. Targeting phospholamban by gene transfer in human heart failure//Circulation. -2002. -Vol. 105, № 8. -P.904-907.
Nicolaou P., Rodriguez P., Ren X. et al. et al. Inducible expression of active protein phosphatase-1 et al. inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury//Circ Res. -2009. -Apr. 24. -Vol. 104, № 8. -P. 1012-1020.
Pathak A., Baldwin B., Kranias E.G. Key protein alterations associated with hyperdynamic cardiac function: insights based on proteomic analysis of the protein phosphatase 1 inhibitor-1 overexpressing hearts//Hellenic J. Cardiol. -2007. -Vol. 48, № 1. -P. 30-36.
Pathak A., del Monte F., Zhao W. et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1//Circ. Res. -2005. -Vol. 96, № 7. -P. 756-766.
Most P., Pleger S.T., Volkers M. et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium//J. of Clinical Investigation. -2004. -Vol. 114. -P. 1550-1563.
Pleger S.T., Most P., Boucher M. et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue//Circulation. -2007. -Vol. 115, № 19. -P. 2506-2515.
Most P., Koch W.J. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy//Future Cardiol. -2007. -Vol. 3, № 1. -P. 5-11.
Kho C., Lee A., Jeong D. et al. SUMO1-dependent modulation of SERCA2a in heart failure//Nature. -2011. -Vol. 4, № 77 (7366). -P. 601-605.
Ghadge S.K., Muhlstedt S., Ozcelik C., Bader M. SDF-1alpha as a therapeutic stem cell homing factor in myocardial infarction//Pharmacol. Ther. -2011. -Vol. 129, № 1. -P. 97-108.
Kawase Y., Ladage D., Hajjar R.J. Rescuing the failing heart by targeted gene transfer//J. Am. Coll Cardiol. -2011. -Vol. 57, 10. -P. 1169-1180.
Chen J., Chemaly E., Liang L. et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury//Am. J. Pathol. -2010. -Vol. 176, № 4. -P. 1705-1715.
LaRocca T.J., Schwarzkopf M., Altman P. et al. Beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4//J. Cardiovasc. Pharmacol. -2010. -Vol. 56, 5. -P. 548-559.
Cottage C.T., Bailey B., Fischer K.M. et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase//Circ. Res. -2010. -Vol. 106, № 5. -P. 891-901.
Fischer K.M., Cottage C.T., Wu W. et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase//Circulation. -2009. -Vol. 120, № 21. -P.2077-2087.
Matsui T., Tao J., del Monte F. et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo//Circulation. -2001. -Vol. 104, № 3. -P. 330-335.
Fomicheva E.V., Turner I.I., Edwards T.G. et al. Double oxygen-sensing vector system for robust hypoxia/ischemia-regulated gene induction in cardiac muscle in vitro and in vivo//Mol. Ther. -2008. -Vol. 16, № 9. -P. 1594-1601.
Giuseppe Rengo, Gennaro Pagano, Pasquale Perrone Filardi, Grazia Daniela Femminella et al. Prognostic value of lymphocyte G proteincoupled receptor kinase-2 protein levels in patients with heart failure//Circ Res. -2016. -Apr. 1. -Vol. 118, № 7. -P. 1116-1124.
Sikkel M.B., Hayward C., MacLeod K.T., Harding S.E., Lyon A.R. SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope//Br. J. Pharmacol. -2014. -Jan. -Vol. 171, № 1. -P. 38-54.
Hajjar, Roger J. et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure//J. of Cardiac Failure. -2008. -Vol. 14, № 5. -P. 355-367.
Jaski B.E., Jessup M.L., Mancini D.M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial//J. of cardiac failure. -2009. -Vol. 15, № 3. -P.171-181.
Mariell Jessup, Barry Greenberg, Donna Mancini, Thomas Cappola et al. On behalf of the сalcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID) investigators background-adeno-associated virus type 1/sarcoplasmic reticulum Ca2+-ATPase was assessed in a randomized, double-blind, placebocontrolled, phase 2 study in patients with advanced heart failure//Circulation. -2011. -Vol. 124. -P. 304-313.
Barry Greenberg, Javed Butler et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebocontrolled, phase 2b trial//Lancet. -2016. -Mar. 19. -Vol. 387 (10024). -P. 1178-1186.

Еще

Статья